Earnings ·
Cellectis reported financial results for the second quarter ended June 30, 2026
CLLSCellectis S.A.
Cellectis reported financial results for the second quarter ended June 30, 2026. The company held $169 million in cash and equivalents, providing a runway into Q4 2027. Revenues decreased to $14.5 million from $30.2 million in the prior year period due to lower activity under the AstraZeneca collaboration agreement. R&D expenses rose to $52.2 million as clinical development costs for lasme-cel and eti-cel increased. The net loss attributable to shareholders was $39.6 million, or $0.39 per share, compared to a $41.9 million loss in the same period last year. Clinically, Cellectis received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia and presented full Phase 1 data from the BALLI-01 trial at EHA 2026 showing a 100% overall response rate in the target population. The company also presented translational data for eti-cel in non-Hodgkin lymphoma. Cellectis is a clinical-stage biotechnology company developing gene-edited cell and gene therapies.